JP Morgan downgraded Genzyme Corp. (NYSE: GENZ) after the Food and Drug Administration informed the biotechnology firm that third party inspectors may have to be hired to monitor one of its manufacturing plants. The stock price tumbled $3.88 to $51.45.
